Experts Evaluated Rare Kidney Cancer Treatment Options
Researchers have analyzed new combination therapies for patients diagnosed with non-clear cell renal cell carcinoma.
Updated on Oct. 7, 2026 in Cancer
Medical experts recently reviewed clinical trial data for new treatment strategies targeting non-clear cell renal cell carcinoma. The findings offer a path forward for patients with these rarer kidney cancer subtypes, which have historically lacked effective options.
Why it matters
Non-clear cell renal cell carcinoma requires alternative treatment strategies beyond historical TKI monotherapy. This shift toward molecular-based approaches aims to improve outcomes for patients whose cancer subtypes previously showed limited response to standard care.
Experts reviewed results from two clinical trials evaluating IO-TKI and IO-IO combination therapies. These studies assessed lenvatinib plus pembrolizumab and ipilimumab plus nivolumab for patients with varying types of non-clear cell renal cell carcinoma.
The players
KEYNOTE-B61
A clinical trial evaluating the combination of lenvatinib and pembrolizumab in patients with non-clear cell renal cell carcinoma.
SUNNIFORECAST
A clinical trial comparing ipilimumab plus nivolumab to standard-of-care therapy for previously untreated non-clear cell renal cell carcinoma.
The details
The treatment approach relies on identifying specific tumor subtypes through molecular characterization, which helps determine the likelihood of response to immune checkpoint inhibitors. While chromophobe renal cell carcinoma shows limited sensitivity to immune-based approaches, findings indicate that FH-deficient subtypes demonstrate activity with TKI-IO combinations. These strategies pair targeted tyrosine kinase inhibitors with immunotherapy to better address the biological drivers of non-clear cell cancers.
Timeline
October 7, 2026: The review of clinical treatment strategies was published.
Health Landscape
This development represents a shift away from the historical TKI monotherapy standard of care for renal cell carcinoma. It reflects a broader movement toward molecular-informed treatment protocols for rare cancer subtypes.
Patients diagnosed with non-clear cell renal cell carcinoma should discuss with their physician whether molecular characterization of their tumor is recommended. Understanding these specific subtypes is essential for identifying which modern combination therapies may be appropriate for their care.
The takeaway
The move toward molecular characterization in rare kidney cancers marks a significant step beyond older, less-effective monotherapies. Always ask your oncologist if your specific tumor subtype has been genomically tested to help guide treatment conversations.
Further reading
For more information on the evolving standards for tumor management, visit our Cancer section.
